Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi: Vir Biotechnology Inc (VIR)

Vir Biotechnology, Inc. (VIR) is actively developing a monoclonal antibody pipeline to combat hepatitis B and Delta. Its unique immunological platform enables the neutralization of viruses at early stages, ensuring global security. Revenues are based on royalties from COVID drugs and future releases. This chart in the GURU.Markets terminal illustrates quarterly EBITDA volume, where 0.00 shows the value of this parameter to assess current success.

VIR Vir Biotechnology, Inc.: Bathi sadurunge mbayar bunga, pajak, lan amortisasi ing interval 23.11.2025 - 12.11.2026

Vir Biotechnology (VIR) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:

Bagan bursa Vir Corp|VIR - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Vir Biotechnology|VIR - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Nilai Buku saben Saham Vir Biotechnology|VIR - Nilai Buku Perusahaan|Kapitalisasi Pasar marang Nilai Buku vir.bio|VIR - Gunggung Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

Utang marang Ekuitas Vir Biotechnology, Inc.|VIR - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Vir Biotechnology Inc|VIR - Utang perusahaan|Rasio utang marang aset resik Vir Biotechnology|VIR - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Vir Biotechnology|Likuiditas cepet vir.bio

- data bathi bisnis lan rasio investasi:

VIR - Bathi resik|Prakiraan bathi perusahaan Vir Biotechnology, Inc.|VIR - Rasio rega marang bathi|Rasio prakiraan rega marang bathi vir.bio|VIR - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Vir Biotechnology|VIR - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Vir Biotechnology|VIR - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan vir.bio|VIR - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Vir Biotechnology, Inc.

Analisis kabeh metrik perusahaan:Vir Corp

Investors must critically assess the operational risks of Vir Biotechnology, Inc. (VIR), excluding random market fluctuations. The integration of ESG standards and the expansion of therapy accessibility confirm the strategic resilience of the business model. The EBITDA financial metric captures the actual cash flow from core operations, stripped of non-cash charges. The upward trend of this indicator mathematically confirms the scaling of the business. Positive profit dynamics guarantee the fundamental reliability of Vir Biotechnology, Inc. (VIR).

Analisis pesaing Vir Biotechnology, Inc.